Cynvenio Biosystems
Region
Southern California
Fund
Anthem Venture Partners II
Industry
Other
Contributing Partners
Samit Varma
About the Company
Cynvenio’s technology enables the comprehensive molecular analysis of cancer via circulating tumor cells isolated from a simple blood draw of individual patients. The information derived from this liquid biopsy is used to select targeted therapy for the patient and to drive a greater understanding of the molecular mechanisms of cancer towards the discovery of novel therapeutic solutions. This technology has the potential to validate therapies, reduce adverse reactions in patients, and increase the efficacy of cancer treatment.
Company Heritage
Cynvenio Biosystems, Inc. was launched in January 2008 on the strength of foundational technology developed at the University of California, Santa Barbara (UCSB) with a vision to change the field of molecular diagnostics. The founders include Fred Gluck, the former Managing Partner of McKinsey & Company and Amgen director, Dr. Alan Heeger, a physicist and Nobel laureate for Chemistry (2000) and Dr. Hyongsok Soh, an expert in molecular bioseparation and microfluidics.
